Novartis and Lonza in biologics partnership
This article was originally published in Scrip
Executive Summary
Novartishas signed an agreement with the Swiss firmLonza to help it develop and manufacture products in its Biologics unit's pipeline. The partnership should allow Novartis to speed up the development of its potential biologic medicines, which now account for a quarter of its pipeline, by using Lonza's expertise in biotech process development and manufacturing.